person · Reporting owner

FLATLEY JAY T

Disclosed activity across 7 companies

Tapewire entity: 35935
SEC CIK: 0001189130

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Denali Therapeutics Inc.DNLI · Entity 1735	Director	June 03, 2026	June 05, 2026
ILLUMINA, INC.ILMN · Entity 3137	Director	May 18, 2021	May 20, 2021
Rivian Automotive, Inc. / DERIVN · Entity 3226	Director	June 22, 2026	June 23, 2026
Senti Biosciences Holdings, Inc.DYNS · Entity 7935	Director	May 25, 2021	May 26, 2021

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Denali Therapeutics Inc.

Report date June 03, 2026 · Filed June 05, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	22,628	Reported balance After 2026-06-03 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2026-06-03 · Grant · Acquired 6,408 · Balance 22,628 F1: Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. F2: Includes 6,408 unvested RSUs.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.66 · Expires 2036-06-03	Direct	19,226	Reported balance After 2026-06-03 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-06-03 · Grant · Acquired 19,226 · Balance 19,226 F4: 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.
Common StockSEC Table I · non-derivative	IndirectSee footnote	336,313	Reported balance Holding disclosure · report date 2026-06-03 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 336,313 F3: The shares are held of record by The Flatley Family Trust, for which the Reporting Person serves as a trustee.

Filing footnotes · ownership attribution and instrument terms

F1: Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.

F2: Includes 6,408 unvested RSUs.

F3: The shares are held of record by The Flatley Family Trust, for which the Reporting Person serves as a trustee.

F4: 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.

ILLUMINA, INC.

Report date May 18, 2021 · Filed May 20, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	148,933	Reported balance After 2021-05-18 transaction · row 1 1 source row Row 1 · 2021-05-18 · Sale · Disposed 4,000 · Balance 148,933 F1: The sale was made pursuant to a 10b5-1 plan.
Common StockSEC Table I · non-derivative	IndirectBy Daughters	3,500	Reported balance Holding disclosure · report date 2021-05-18 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 3,500

Filing footnotes · ownership attribution and instrument terms

F1: The sale was made pursuant to a 10b5-1 plan.

Rivian Automotive, Inc. / DE

Report date June 22, 2026 · Filed June 23, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A Common StockSEC Table I · non-derivative	Direct	179,515	Reported balance After 2026-06-22 transaction · row 1 1 source row Row 1 · 2026-06-22 · Grant · Acquired 17,445 · Balance 179,515 F1: Represents an award of 17,445 restricted stock units ("RSUs") which will vest on the first anniversary of the grant date.

Filing footnotes · ownership attribution and instrument terms

F1: Represents an award of 17,445 restricted stock units ("RSUs") which will vest on the first anniversary of the grant date.

Senti Biosciences Holdings, Inc.

Report date May 25, 2021 · Filed May 26, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A common stockSEC Table I · non-derivative	IndirectSee footnote	10,733	Reported balance Holding disclosure · report date 2021-05-25 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 10,733 F1: Up to 900 of these shares of Class A common stock will be forfeited in the event the underwriters for the Issuer's initial public offering do not exercise in full their overallotment option in connection with that offering, all as described in the Issuer's prospectus on Form S-1 filed on May 7, 2021 (the "Prospectus"). F2: Dynamics Sponsor LLC, a Delaware limited liability company, (the "Sponsor") is the record holder of these shares. The Sponsor is governed by a board of managers consisting of Omid Farokhzad and Mostafa Ronaghi who hold an economic interest therein. Any action by the Sponsor with respect to Issuer or the shares reported above, including voting and dispositive decisions, requires unanimous approval of the managers.
Class B common stockSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	IndirectSee footnote	Not disclosed	Reported balance Holding disclosure · report date 2021-05-25 · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · Balance Not disclosed F3: These shares of Class B common stock will automatically convert on a one-for-one basis (subject to adjustment) into Class A common stock for no additional consideration at the time of the initial business combination by the Issuer, subject to the adjustments described in the Prospectus. The shares of Class B Common Stock have no expiration date. F4: Up to 4,894 of these shares of Class B common stock will be forfeited in the event the underwriters for the Issuer's initial public offering do not exercise in full their overallotment option in connection with that offering, all as described in the Prospectus. F2: Dynamics Sponsor LLC, a Delaware limited liability company, (the "Sponsor") is the record holder of these shares. The Sponsor is governed by a board of managers consisting of Omid Farokhzad and Mostafa Ronaghi who hold an economic interest therein. Any action by the Sponsor with respect to Issuer or the shares reported above, including voting and dispositive decisions, requires unanimous approval of the managers.

Filing footnotes · ownership attribution and instrument terms

F1: Up to 900 of these shares of Class A common stock will be forfeited in the event the underwriters for the Issuer's initial public offering do not exercise in full their overallotment option in connection with that offering, all as described in the Issuer's prospectus on Form S-1 filed on May 7, 2021 (the "Prospectus").

F2: Dynamics Sponsor LLC, a Delaware limited liability company, (the "Sponsor") is the record holder of these shares. The Sponsor is governed by a board of managers consisting of Omid Farokhzad and Mostafa Ronaghi who hold an economic interest therein. Any action by the Sponsor with respect to Issuer or the shares reported above, including voting and dispositive decisions, requires unanimous approval of the managers.

F3: These shares of Class B common stock will automatically convert on a one-for-one basis (subject to adjustment) into Class A common stock for no additional consideration at the time of the initial business combination by the Issuer, subject to the adjustments described in the Prospectus. The shares of Class B Common Stock have no expiration date.

F4: Up to 4,894 of these shares of Class B common stock will be forfeited in the event the underwriters for the Issuer's initial public offering do not exercise in full their overallotment option in connection with that offering, all as described in the Prospectus.

Past disclosures · reporting ended (3)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

COHERENT INC

Report date July 01, 2022 · Filed July 01, 2022

Section 16 reporting ended · disclosed 2022-07-01. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy Family Trust	0	Reported balance After 2022-07-01 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2022-07-01 · Disposition to issuer · Disposed 43,018 · Balance 0 F1: On July 1, 2022, II-VI Incorporated ("Buyer"), acquired the Issuer pursuant to that certain Agreement and Plan of Merger entered into by and among the Issuer, Buyer and Watson Merger Sub Inc, a direct, wholly owned subsidiary of Buyer ("Merger Sub"), dated as of March 25, 2021 (the "Merger Agreement"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer, with the Issuer surviving such merger (the "Merger"). F2: At the effective time of the Merger (the "Effective Time"), each outstanding share of the Issuer's common stock (other than certain excluded shares) automatically converted into the right to receive $220.00 in cash, without interest (the "Cash Consideration"), plus 0.91 of a validly issued, fully paid and nonassessable share of Buyer (the "Merger Consideration").

Filing footnotes · ownership attribution and instrument terms

F1: On July 1, 2022, II-VI Incorporated ("Buyer"), acquired the Issuer pursuant to that certain Agreement and Plan of Merger entered into by and among the Issuer, Buyer and Watson Merger Sub Inc, a direct, wholly owned subsidiary of Buyer ("Merger Sub"), dated as of March 25, 2021 (the "Merger Agreement"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer, with the Issuer surviving such merger (the "Merger").

F2: At the effective time of the Merger (the "Effective Time"), each outstanding share of the Issuer's common stock (other than certain excluded shares) automatically converted into the right to receive $220.00 in cash, without interest (the "Cash Consideration"), plus 0.91 of a validly issued, fully paid and nonassessable share of Buyer (the "Merger Consideration").

Juno Therapeutics, Inc.

Report date March 05, 2018 · Filed March 07, 2018

Section 16 reporting ended · disclosed 2018-03-07. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy the Flatley Family Trust	Reported balance After 2018-03-05 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2018-03-05 · Other · Disposed 31,500 · Balance 0 F1: On January 21, 2018, Juno Therapeutics, Inc. (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Celgene Corporation ("Parent"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent ("Purchaser"). On March 5, 2018, Purchaser irrevocably accepted for payment and promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F2: Pursuant to the terms of the Merger Agreement and the Offer, each share of common stock of the Company held by the Reporting Person was validly tendered for $87.00 per share in cash, without interest and subject to withholding of taxes.
Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.07 · Expires 2027-05-21	Direct	Reported balance After 2018-03-05 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2018-03-05 · Disposition to issuer · Disposed 18,000 · Balance 0 F1: On January 21, 2018, Juno Therapeutics, Inc. (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Celgene Corporation ("Parent"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent ("Purchaser"). On March 5, 2018, Purchaser irrevocably accepted for payment and promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F3: In accordance with their terms, Options held by non-employee directors were converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such Option and (ii) $87.00 less the applicable exercise price.
Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.29 · Expires 2027-06-15	Direct	Reported balance After 2018-03-05 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2018-03-05 · Disposition to issuer · Disposed 12,000 · Balance 0 F1: On January 21, 2018, Juno Therapeutics, Inc. (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Celgene Corporation ("Parent"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent ("Purchaser"). On March 5, 2018, Purchaser irrevocably accepted for payment and promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F3: In accordance with their terms, Options held by non-employee directors were converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such Option and (ii) $87.00 less the applicable exercise price.

Filing footnotes · ownership attribution and instrument terms

F1: On January 21, 2018, Juno Therapeutics, Inc. (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Celgene Corporation ("Parent"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent ("Purchaser"). On March 5, 2018, Purchaser irrevocably accepted for payment and promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent.

F2: Pursuant to the terms of the Merger Agreement and the Offer, each share of common stock of the Company held by the Reporting Person was validly tendered for $87.00 per share in cash, without interest and subject to withholding of taxes.

F3: In accordance with their terms, Options held by non-employee directors were converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such Option and (ii) $87.00 less the applicable exercise price.

Zymergen Inc.

Report date October 19, 2022 · Filed October 20, 2022

Section 16 reporting ended · disclosed 2022-10-20. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2022-10-19 transaction · row 1 1 source row Row 1 · 2022-10-19 · Disposition to issuer · Disposed 144,789 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of July 24, 2022 (the "Merger Agreement"), by and among Ginkgo Bioworks Holdings, Inc. ("Ginkgo"), Pepper Merger Subsidiary Inc. and the Issuer, each share of the Issuer's common stock was cancelled and converted into a right to receive 0.9179 of a share of Class A common stock of Ginkgo (the "Merger Consideration"), together with cash in lieu of any fractional shares of Class A common stock of Ginkgo.
Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $12.33 · Expires 2031-08-06	Direct	Reported balance After 2022-10-19 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2022-10-19 · Disposition to issuer · Disposed 1,520,000 · Balance 0 F2: Immediately prior to the effective time of the merger (the "Effective Time"), all outstanding Issuer stock options vested in full pursuant to the terms of the agreements governing such stock options. Pursuant to the Merger Agreement, at the Effective Time, each Issuer stock option with an exercise price per share equal to or greater than the Merger Consideration Value (as defined in the Merger Agreement) was cancelled for no consideration.
Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $8.52 · Expires 2029-09-17	Direct	Reported balance After 2022-10-19 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2022-10-19 · Disposition to issuer · Disposed 189,125 · Balance 0 F2: Immediately prior to the effective time of the merger (the "Effective Time"), all outstanding Issuer stock options vested in full pursuant to the terms of the agreements governing such stock options. Pursuant to the Merger Agreement, at the Effective Time, each Issuer stock option with an exercise price per share equal to or greater than the Merger Consideration Value (as defined in the Merger Agreement) was cancelled for no consideration.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger, dated as of July 24, 2022 (the "Merger Agreement"), by and among Ginkgo Bioworks Holdings, Inc. ("Ginkgo"), Pepper Merger Subsidiary Inc. and the Issuer, each share of the Issuer's common stock was cancelled and converted into a right to receive 0.9179 of a share of Class A common stock of Ginkgo (the "Merger Consideration"), together with cash in lieu of any fractional shares of Class A common stock of Ginkgo.

F2: Immediately prior to the effective time of the merger (the "Effective Time"), all outstanding Issuer stock options vested in full pursuant to the terms of the agreements governing such stock options. Pursuant to the Merger Agreement, at the Effective Time, each Issuer stock option with an exercise price per share equal to or greater than the Merger Consideration Value (as defined in the Merger Agreement) was cancelled for no consideration.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 22, 2026 Filed Jun 23, 2026 20:37 UTC	Rivian Automotive, Inc. / DE RIVN · Entity 3226	GrantClass A Common Stock	17,445	$0.00	$0.00	Disclosure SEC source: 0001189130-26-000007 · wk-form4_1782247057.xml · nonDerivative · entry 1 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 179,515 F1 · shares: Represents an award of 17,445 restricted stock units ("RSUs") which will vest on the first anniversary of the grant date. Read SEC document
June 03, 2026 Filed Jun 5, 2026 20:46 UTC	Denali Therapeutics Inc. DNLI · Entity 1735	GrantStock Option (right to buy) · Derivative	19,226	$0.00 Strike: $19.66	$0.00	Disclosure SEC source: 0001189130-26-000005 · wk-form4_1780692384.xml · derivative · entry 3 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,226 Underlying: Common Stock · 19,226 shares Expires 2036-06-03 F4 · derivative.exercise_date: 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. Read SEC document
June 03, 2026 Filed Jun 5, 2026 20:46 UTC	Denali Therapeutics Inc. DNLI · Entity 1735	GrantCommon Stock	6,408	$0.00	$0.00	Disclosure SEC source: 0001189130-26-000005 · wk-form4_1780692384.xml · nonDerivative · entry 1 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,628 F1 · shares: Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. F2 · balance_after: Includes 6,408 unvested RSUs. Read SEC document
June 18, 2025 Filed Jun 20, 2025 21:16 UTC	Rivian Automotive, Inc. / DE RIVN · Entity 3226	GrantClass A Common Stock	16,812	$0.00	$0.00	Disclosure SEC source: 0001189130-25-000004 · wk-form4_1750454170.xml · nonDerivative · entry 1 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 160,820 F1 · shares: Represents an award of 16,812 restricted stock units ("RSUs") which will vest on the first anniversary of the grant date. Read SEC document
June 03, 2025 Filed Jun 5, 2025 20:33 UTC	Denali Therapeutics Inc. DNLI · Entity 1735	GrantStock Option (right to buy) · Derivative	18,111	$0.00 Strike: $13.93	$0.00	Disclosure SEC source: 0001714899-25-000141 · wk-form4_1749155513.xml · derivative · entry 3 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,111 Underlying: Common Stock · 18,111 shares Expires 2035-06-03 F4 · derivative.exercise_date: 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. Read SEC document
June 03, 2025 Filed Jun 5, 2025 20:33 UTC	Denali Therapeutics Inc. DNLI · Entity 1735	GrantCommon Stock	6,037	$0.00	$0.00	Disclosure SEC source: 0001714899-25-000141 · wk-form4_1749155513.xml · nonDerivative · entry 1 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,220 F1 · shares: Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. F2 · balance_after: Includes 6,037 unvested RSUs. Read SEC document
June 18, 2024 Filed Jun 21, 2024 20:52 UTC	Rivian Automotive, Inc. / DE RIVN · Entity 3226	GrantClass A Common Stock	24,224	$0.00	$0.00	Disclosure SEC source: 0001628280-24-029354 · wk-form4_1719003158.xml · nonDerivative · entry 1 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 144,008 F1 · shares: Represents an award of 24,224 restricted stock units ("RSUs") which will vest on the first anniversary of the grant date. Read SEC document
May 31, 2024 Filed Jun 4, 2024 22:28 UTC	Denali Therapeutics Inc. DNLI · Entity 1735	GrantStock Option (right to buy) · Derivative	17,901	$0.00 Strike: $18.56	$0.00	Disclosure SEC source: 0001714899-24-000135 · wk-form4_1717540113.xml · derivative · entry 3 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,901 Underlying: Common Stock · 17,901 shares Expires 2034-05-31 F5 · derivative.exercise_date: 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. Read SEC document
May 31, 2024 Filed Jun 4, 2024 22:28 UTC	Denali Therapeutics Inc. DNLI · Entity 1735	GrantCommon Stock	5,967	$0.00	$0.00	Disclosure SEC source: 0001714899-24-000135 · wk-form4_1717540113.xml · nonDerivative · entry 1 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,183 F1 · shares: Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. F2 · balance_after: Includes 5,967 unvested RSUs. F3 · balance_after: Includes shares previously reported as held by The Flatley Family Trust. Read SEC document
April 17, 2024 Filed Mar 5, 2026 22:10 UTC	Rivian Automotive, Inc. / DE RIVN · Entity 3226	PurchaseClass A Common Stock	1,250	$8.84	$11,055.00	Disclosure SEC source: 0001189130-26-000003 · wk-form4_1772748609.xml · nonDerivative · entry 8 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 162,070 F2 · kind: The Reporting Person's sale of 490 shares Class A common stock on October 25, 2023 at a price of $17.0726 per share was matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of 490 shares, with the Reporting Person's purchase of 1,250 shares of Class A common stock on April 17, 2024 at a price of $8.844 per share. The Reporting Person paid to the Issuer $4,032.01, representing the full amount of the profit realized in connection with the short-swing transaction. Read SEC document
October 23, 2023 Filed Mar 5, 2026 22:10 UTC	Rivian Automotive, Inc. / DE RIVN · Entity 3226	SaleClass A Common Stock	490	$17.07	$8,365.57	Disclosure SEC source: 0001189130-26-000003 · wk-form4_1772748609.xml · nonDerivative · entry 7 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 160,820 F2 · kind: The Reporting Person's sale of 490 shares Class A common stock on October 25, 2023 at a price of $17.0726 per share was matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of 490 shares, with the Reporting Person's purchase of 1,250 shares of Class A common stock on April 17, 2024 at a price of $8.844 per share. The Reporting Person paid to the Issuer $4,032.01, representing the full amount of the profit realized in connection with the short-swing transaction. Read SEC document
July 06, 2023 Filed Mar 5, 2026 22:10 UTC	Rivian Automotive, Inc. / DE RIVN · Entity 3226	PurchaseClass A Common Stock	490	$20.67	$10,130.55	Disclosure SEC source: 0001189130-26-000003 · wk-form4_1772748609.xml · nonDerivative · entry 6 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 161,310 Read SEC document
June 21, 2023 Filed Jun 23, 2023 23:00 UTC	Rivian Automotive, Inc. / DE RIVN · Entity 3226	GrantClass A Common Stock	18,208	$0.00	$0.00	Disclosure SEC source: 0001209191-23-039521 · doc4.xml · nonDerivative · entry 1 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 119,784 F1 · shares: Represents an award of 18,208 restricted stock units ("RSUs") which will vest on the first anniversary of the grant date. The RSUs will settle in shares of the Issuer's Class A Common Stock upon vesting. Read SEC document
June 01, 2023 Filed Jun 5, 2023 22:03 UTC	Denali Therapeutics Inc. DNLI · Entity 1735	GrantStock Option (right to buy) · Derivative	12,649	$0.00 Strike: $30.92	$0.00	Disclosure SEC source: 0001714899-23-000095 · wk-form4_1686002576.xml · derivative · entry 2 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,649 Underlying: Common Stock · 12,649 shares Expires 2033-06-01 F5 · derivative.exercise_date: 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. Read SEC document
June 01, 2023 Filed Jun 5, 2023 22:03 UTC	Denali Therapeutics Inc. DNLI · Entity 1735	GrantCommon Stock	4,216	$0.00	$0.00	Disclosure SEC source: 0001714899-23-000095 · wk-form4_1686002576.xml · nonDerivative · entry 1 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 340,529 F1 · shares: Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. F2 · shares: Shares will be issued directly to The Flatley Family Trust. F3 · balance_after: Includes 4,216 unvested RSUs. F4 · ownership.nature: The shares are held of record by The Flatley Family Trust, for which the Reporting Person serves as a trustee. Read SEC document
December 13, 2022 Filed Mar 5, 2026 22:10 UTC	Rivian Automotive, Inc. / DE RIVN · Entity 3226	SaleClass A Common Stock	57	$25.75	$1,467.60	Disclosure SEC source: 0001189130-26-000003 · wk-form4_1772748609.xml · nonDerivative · entry 5 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 160,820 Read SEC document
December 13, 2022 Filed Mar 5, 2026 22:10 UTC	Rivian Automotive, Inc. / DE RIVN · Entity 3226	SaleClass A Common Stock	3	$24.99	$74.97	Disclosure SEC source: 0001189130-26-000003 · wk-form4_1772748609.xml · nonDerivative · entry 4 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 160,877 Read SEC document
October 19, 2022 Filed Oct 20, 2022 00:17 UTC	Zymergen Inc. ZY · Entity 122955	Disposition to issuerStock Options · Derivative	189,125	$0.00 Strike: $8.52	$0.00	Disclosure SEC source: 0001645842-22-000149 · wf-form4_166622506302580.xml · derivative · entry 3 FLATLEY JAY T · CIK 0001189130 · Director · Chairman and Acting CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 189,125 shares Expires 2029-09-17 F2 · derivative.exercise_date: Immediately prior to the effective time of the merger (the "Effective Time"), all outstanding Issuer stock options vested in full pursuant to the terms of the agreements governing such stock options. Pursuant to the Merger Agreement, at the Effective Time, each Issuer stock option with an exercise price per share equal to or greater than the Merger Consideration Value (as defined in the Merger Agreement) was cancelled for no consideration. Read SEC document
October 19, 2022 Filed Oct 20, 2022 00:17 UTC	Zymergen Inc. ZY · Entity 122955	Disposition to issuerStock Options · Derivative	1,520,000	$0.00 Strike: $12.33	$0.00	Disclosure SEC source: 0001645842-22-000149 · wf-form4_166622506302580.xml · derivative · entry 2 FLATLEY JAY T · CIK 0001189130 · Director · Chairman and Acting CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,520,000 shares Expires 2031-08-06 F2 · derivative.exercise_date: Immediately prior to the effective time of the merger (the "Effective Time"), all outstanding Issuer stock options vested in full pursuant to the terms of the agreements governing such stock options. Pursuant to the Merger Agreement, at the Effective Time, each Issuer stock option with an exercise price per share equal to or greater than the Merger Consideration Value (as defined in the Merger Agreement) was cancelled for no consideration. Read SEC document
October 19, 2022 Filed Oct 20, 2022 00:17 UTC	Zymergen Inc. ZY · Entity 122955	Disposition to issuerCommon Stock	144,789	Not disclosed	Not disclosed	Disclosure SEC source: 0001645842-22-000149 · wf-form4_166622506302580.xml · nonDerivative · entry 1 FLATLEY JAY T · CIK 0001189130 · Director · Chairman and Acting CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of July 24, 2022 (the "Merger Agreement"), by and among Ginkgo Bioworks Holdings, Inc. ("Ginkgo"), Pepper Merger Subsidiary Inc. and the Issuer, each share of the Issuer's common stock was cancelled and converted into a right to receive 0.9179 of a share of Class A common stock of Ginkgo (the "Merger Consideration"), together with cash in lieu of any fractional shares of Class A common stock of Ginkgo. Read SEC document
July 01, 2022 Filed Jul 1, 2022 16:32 UTC	COHERENT INC COHR · Entity 125737	Disposition to issuerCommon Stock	43,018	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-22-076874 · tm2220124-8_4seq1.xml · nonDerivative · entry 1 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Trust Disclosed balance after: 0 F1 · kind: On July 1, 2022, II-VI Incorporated ("Buyer"), acquired the Issuer pursuant to that certain Agreement and Plan of Merger entered into by and among the Issuer, Buyer and Watson Merger Sub Inc, a direct, wholly owned subsidiary of Buyer ("Merger Sub"), dated as of March 25, 2021 (the "Merger Agreement"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer, with the Issuer surviving such merger (the "Merger"). F2 · price: At the effective time of the Merger (the "Effective Time"), each outstanding share of the Issuer's common stock (other than certain excluded shares) automatically converted into the right to receive $220.00 in cash, without interest (the "Cash Consideration"), plus 0.91 of a validly issued, fully paid and nonassessable share of Buyer (the "Merger Consideration"). Read SEC document
June 06, 2022 Filed Jun 8, 2022 21:35 UTC	Rivian Automotive, Inc. / DE RIVN · Entity 3226	GrantClass A Common Stock	8,960	$0.00	$0.00	Disclosure SEC source: 0001209191-22-035133 · doc4.xml · nonDerivative · entry 1 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,576 F1 · shares: Represents an award of 8,960 restricted stock units ("RSUs") which will vest on the first anniversary of the grant date. The RSUs will settle in shares of the Issuer's Class A Common Stock upon vesting. Read SEC document
June 02, 2022 Filed Jun 7, 2022 00:07 UTC	Denali Therapeutics Inc. DNLI · Entity 1735	GrantStock Option (right to buy) · Derivative	17,959	$0.00 Strike: $24.27	$0.00	Disclosure SEC source: 0001714899-22-000092 · wf-form4_165456046364331.xml · derivative · entry 2 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,959 Underlying: Common Stock · 17,959 shares Expires 2032-06-02 F5 · derivative.exercise_date: 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. Read SEC document
June 02, 2022 Filed Jun 7, 2022 00:07 UTC	Denali Therapeutics Inc. DNLI · Entity 1735	GrantCommon Stock	5,986	$0.00	$0.00	Disclosure SEC source: 0001714899-22-000092 · wf-form4_165456046364331.xml · nonDerivative · entry 1 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 336,313 F1 · shares: Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. F2 · shares: Shares will be issued directly to The Flatley Family Trust. F3 · balance_after: Includes 5,986 unvested restricted stock units. F4 · ownership.nature: The shares are held of record by The Flatley Family Trust, for which the Reporting Person serves as a trustee. Read SEC document
May 26, 2022 Filed May 31, 2022 21:36 UTC	Rivian Automotive, Inc. / DE RIVN · Entity 3226	PurchaseClass A Common Stock	40,000	$29.31	$1,172,400.00	Disclosure SEC source: 0001209191-22-032925 · doc4.xml · nonDerivative · entry 1 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,616 F1 · price: The price reported is a weighted average purchase price. The shares were purchased in multiple transactions at prices ranging from $29.21 to $29.33, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document
May 13, 2022 Filed Mar 5, 2026 22:10 UTC	Rivian Automotive, Inc. / DE RIVN · Entity 3226	PurchaseClass A Common Stock	60	$26.83	$1,609.99	Disclosure SEC source: 0001189130-26-000003 · wk-form4_1772748609.xml · nonDerivative · entry 3 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 160,880 F1 · kind: The Reporting Person's sale of 30 shares Class A common stock on January 26, 2022 at a price of $62.2214 per share was matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of 30 shares, with the Reporting Person's purchase of 60 shares of Class A common stock on May 13, 2022 at a price of $26.8331 per share. The Reporting Person paid to the Issuer $1,061.65, representing the full amount of the profit realized in connection with the short-swing transaction. Read SEC document
January 26, 2022 Filed Mar 5, 2026 22:10 UTC	Rivian Automotive, Inc. / DE RIVN · Entity 3226	SaleClass A Common Stock	30	$62.22	$1,866.64	Disclosure SEC source: 0001189130-26-000003 · wk-form4_1772748609.xml · nonDerivative · entry 2 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 160,820 F1 · kind: The Reporting Person's sale of 30 shares Class A common stock on January 26, 2022 at a price of $62.2214 per share was matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of 30 shares, with the Reporting Person's purchase of 60 shares of Class A common stock on May 13, 2022 at a price of $26.8331 per share. The Reporting Person paid to the Issuer $1,061.65, representing the full amount of the profit realized in connection with the short-swing transaction. Read SEC document
January 11, 2022 Filed Mar 5, 2026 22:10 UTC	Rivian Automotive, Inc. / DE RIVN · Entity 3226	PurchaseClass A Common Stock	30	$82.84	$2,485.13	Disclosure SEC source: 0001189130-26-000003 · wk-form4_1772748609.xml · nonDerivative · entry 1 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 160,850 Read SEC document
November 17, 2021 Filed Nov 19, 2021 21:30 UTC	Zymergen Inc. ZY · Entity 122955	PurchaseCommon Stock	100,000	$10.00	$1,000,000.00	Disclosure SEC source: 0001645842-21-000040 · wf-form4_163735744097473.xml · nonDerivative · entry 1 FLATLEY JAY T · CIK 0001189130 · Director · Chairman and Acting CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,789 Read SEC document
November 15, 2021 Filed Nov 18, 2021 00:47 UTC	Rivian Automotive, Inc. / DE RIVN · Entity 3226	PurchaseClass A Common Stock	20,000	$78.00	$1,560,000.00	Disclosure SEC source: 0000899243-21-045169 · doc4.xml · nonDerivative · entry 1 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,616 Read SEC document
August 06, 2021 Filed Aug 10, 2021 00:50 UTC	Zymergen Inc. ZY · Entity 122955	GrantStock Options · Derivative	1,520,000	$0.00 Strike: $12.33	$0.00	Disclosure SEC source: 0001140361-21-027648 · form4.xml · derivative · entry 1 FLATLEY JAY T · CIK 0001189130 · Director · Chairman and Acting CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,520,000 Underlying: Common Stock · 1,520,000 shares Expires 2031-08-06 F1 · derivative.exercise_date: The Options vest in eight substantially equal installments on each quarterly anniversary of August 2, 2021 (the date of Reporting Person's appointment as Acting Chief Executive Officer), subject to Reporting Person's continued service as Acting Chief Executive Officer, Chairman of the Board of Directors or Lead Independent Director of the Board of Directors through such date. Read SEC document
June 02, 2021 Filed Jun 4, 2021 22:33 UTC	Denali Therapeutics Inc. DNLI · Entity 1735	GrantStock Option (right to buy) · Derivative	6,222	$0.00 Strike: $63.76	$0.00	Disclosure SEC source: 0001209191-21-038380 · doc4.xml · derivative · entry 2 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,222 Underlying: Common Stock · 6,222 shares Expires 2031-06-02 F4 · derivative.exercise_date: 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. Read SEC document
June 02, 2021 Filed Jun 4, 2021 22:33 UTC	Denali Therapeutics Inc. DNLI · Entity 1735	GrantCommon Stock	2,074	$0.00	$0.00	Disclosure SEC source: 0001209191-21-038380 · doc4.xml · nonDerivative · entry 1 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 330,327 F1 · shares: Shares will be issued directly to The Flatley Family Trust. F2 · shares: Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. F3 · ownership.nature: The shares are held of record by The Flatley Family Trust, for which the Reporting Person serves as a trustee. Read SEC document
June 01, 2021 Filed Jun 4, 2021 00:53 UTC	Denali Therapeutics Inc. DNLI · Entity 1735	Exercise / conversionRestricted Stock Units · Derivative	3,253	$0.00	$0.00	Disclosure SEC source: 0001209191-21-038039 · doc4.xml · derivative · entry 2 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,253 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. F4 · derivative.exercise_date: 100% of the restricted stock units vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. F4 · derivative.expiration_date: 100% of the restricted stock units vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. Read SEC document
June 01, 2021 Filed Jun 4, 2021 00:53 UTC	Denali Therapeutics Inc. DNLI · Entity 1735	Exercise / conversionCommon Stock	3,253	$0.00	$0.00	Disclosure SEC source: 0001209191-21-038039 · doc4.xml · nonDerivative · entry 1 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 328,253 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares were issued directly to The Flatley Family Trust. F2 · ownership.nature: The shares are held of record by The Flatley Family Trust, for which the Reporting Person serves as a trustee. Read SEC document
May 18, 2021 Filed May 20, 2021 20:51 UTC	ILLUMINA, INC. ILMN · Entity 3137	SaleCommon Stock	4,000	$379.53	$1,518,120.00	Disclosure SEC source: 0001127602-21-017616 · form4.xml · nonDerivative · entry 1 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,933 F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document
May 06, 2021 Filed May 10, 2021 17:09 UTC	COHERENT INC COHR · Entity 125737	GrantCommon Stock	856	$0.00	$0.00	Disclosure SEC source: 0001179110-21-005074 · edgar.xml · nonDerivative · entry 1 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 856 F1 · shares: On May 6, 2021 the Reporting Person was granted 856 Restricted Stock Units which will vest no later than February 15, 2022, subject to certain vesting requirements. F2 · balance_after: Reflects 2,148 shares transferred from direct ownership to the trust. Read SEC document
May 04, 2021 Filed May 6, 2021 21:21 UTC	ILLUMINA, INC. ILMN · Entity 3137	SaleCommon Stock	4,000	$384.15	$1,536,600.00	Disclosure SEC source: 0001127602-21-015772 · form4.xml · nonDerivative · entry 1 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,933 F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document
April 26, 2021 Filed Apr 26, 2021 22:58 UTC	Zymergen Inc. ZY · Entity 122955	ConversionConvertible Series D Preferred Stock · Derivative	44,789	$0.00	$0.00	Disclosure SEC source: 0001140361-21-014362 · form4.xml · derivative · entry 2 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 44,789 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Series D Preferred Stock had no expiration date and automatically converted into an equal number common stock upon the closing of the Issuer's initial public offering F1 · derivative.exercise_price: The Series D Preferred Stock had no expiration date and automatically converted into an equal number common stock upon the closing of the Issuer's initial public offering F1 · derivative.exercise_date: The Series D Preferred Stock had no expiration date and automatically converted into an equal number common stock upon the closing of the Issuer's initial public offering F1 · derivative.expiration_date: The Series D Preferred Stock had no expiration date and automatically converted into an equal number common stock upon the closing of the Issuer's initial public offering Read SEC document
April 26, 2021 Filed Apr 26, 2021 22:58 UTC	Zymergen Inc. ZY · Entity 122955	ConversionCommon Stock	44,789	Not disclosed	Not disclosed	Disclosure SEC source: 0001140361-21-014362 · form4.xml · nonDerivative · entry 1 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,789 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series D Preferred Stock had no expiration date and automatically converted into an equal number common stock upon the closing of the Issuer's initial public offering Read SEC document
April 20, 2021 Filed Apr 22, 2021 21:05 UTC	ILLUMINA, INC. ILMN · Entity 3137	SaleCommon Stock	4,000	$401.83	$1,607,320.00	Disclosure SEC source: 0001127602-21-014318 · form4.xml · nonDerivative · entry 1 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,933 F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document
April 06, 2021 Filed Apr 7, 2021 20:41 UTC	ILLUMINA, INC. ILMN · Entity 3137	SaleCommon Stock	4,000	$423.44	$1,693,740.00	Disclosure SEC source: 0001127602-21-013417 · form4.xml · nonDerivative · entry 1 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,933 F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document
March 16, 2021 Filed Mar 18, 2021 23:20 UTC	ILLUMINA, INC. ILMN · Entity 3137	SaleCommon Stock	4,000	$421.06	$1,684,240.00	Disclosure SEC source: 0001127602-21-011480 · form4.xml · nonDerivative · entry 1 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,933 F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document
March 02, 2021 Filed Mar 4, 2021 22:04 UTC	ILLUMINA, INC. ILMN · Entity 3137	SaleCommon Stock	4,000	$444.61	$1,778,440.00	Disclosure SEC source: 0001127602-21-009435 · form4.xml · nonDerivative · entry 1 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,933 F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document
February 16, 2021 Filed Feb 19, 2021 00:08 UTC	ILLUMINA, INC. ILMN · Entity 3137	SaleCommon Stock	250	$494.67	$123,666.25	Disclosure SEC source: 0001127602-21-006557 · form4.xml · nonDerivative · entry 3 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Daughters Disclosed balance after: 3,500 Read SEC document
February 16, 2021 Filed Feb 19, 2021 00:08 UTC	ILLUMINA, INC. ILMN · Entity 3137	SaleCommon Stock	250	$495.51	$123,876.30	Disclosure SEC source: 0001127602-21-006557 · form4.xml · nonDerivative · entry 2 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Daughters Disclosed balance after: 3,750 Read SEC document
February 16, 2021 Filed Feb 19, 2021 00:08 UTC	ILLUMINA, INC. ILMN · Entity 3137	SaleCommon Stock	4,000	$505.26	$2,021,040.00	Disclosure SEC source: 0001127602-21-006557 · form4.xml · nonDerivative · entry 1 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,933 F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document
February 02, 2021 Filed Feb 3, 2021 21:58 UTC	ILLUMINA, INC. ILMN · Entity 3137	SaleCommon Stock	4,000	$444.84	$1,779,360.00	Disclosure SEC source: 0001127602-21-003733 · form4.xml · nonDerivative · entry 1 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,933 F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document
January 19, 2021 Filed Jan 21, 2021 21:38 UTC	ILLUMINA, INC. ILMN · Entity 3137	SaleCommon Stock	4,000	$382.48	$1,529,920.00	Disclosure SEC source: 0001127602-21-002267 · form4.xml · nonDerivative · entry 1 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,933 F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document
January 05, 2021 Filed Jan 7, 2021 00:19 UTC	ILLUMINA, INC. ILMN · Entity 3137	SaleCommon Stock	4,000	$365.27	$1,461,080.00	Disclosure SEC source: 0001127602-21-001149 · form4.xml · nonDerivative · entry 1 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 184,933 F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.